Because of ambiguous and widely debated observations concerning the incidence, trend, and management of TC, we performed this analysis. We drew attention to some events, such as “cancer screening activity”, introduction of noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP) to TC types, possibility of papillary thyroid microcarcinoma (PTMC) active surveillance (AS), occurrence of personalized medicine in TC management, and, finally, COVID-19 pandemic time. Because of the opinion that all changes have been made mostly by PTC, we compared it to the remaining types of TC in terms of incidence, clinical and pathological characteristics, and treatment. We analyzed patients treated in a single surgical center in eastern Europe (Poland). The prevalence of TC significantly increased from 5.15% in 2008 to 13.84% in 2015, and then significantly decreased to 1.33% in 2022 when the COVID-19 pandemic lasted (p< 0.0001). A similar trend was observed for PTC, when the incidence significantly increased to 13.99% in 2015 and then decreased to 1.38% in 2022 (p< 0.0001). At that time, the NIFTP category was introduced, and observation of PTMC began. The prevalence of FTC and MTC also increased until 2015 and then decreased. Significant differences in age, types of surgery, necessity of reoperation, and pTNM between PTCs and other types of TCs were observed. The average age was significantly lower in PTC patients than in patients with the remaining types of TC (p< 0.0001). Four milestones, including NIFTP introduction, the possibility of PTMC AS, personalized cancer medicine, and the COVID-19 pandemic, may have influenced the general statistics of TC.
鉴于甲状腺癌（TC）的发病率、趋势及诊疗方面存在诸多模糊且广泛争议的观察结果，我们开展了此项分析。我们重点关注了若干关键事件，包括“癌症筛查活动”的开展、甲状腺肿瘤分类中引入具有乳头状核特征的非浸润性滤泡性肿瘤（NIFTP）、甲状腺微小乳头状癌（PTMC）主动监测（AS）的实施可能、个体化医疗在TC诊疗中的应用，以及最终新型冠状病毒肺炎（COVID-19）大流行时期的影响。基于“所有变化主要由PTC引起”的观点，我们将其与TC其他亚型在发病率、临床病理特征及治疗方式等方面进行了比较研究。本研究对象为东欧（波兰）单一外科中心收治的患者群体。数据显示：TC患病率从2008年的5.15%显著上升至2015年的13.84%，随后在COVID-19大流行持续的2022年显著下降至1.33%（p<0.0001）。PTC亦呈现相似趋势，其发病率在2015年显著上升至13.99%，随后在2022年降至1.38%（p<0.0001）。在此期间，NIFTP分类被正式引入临床实践，PTMC观察策略开始实施。滤泡性甲状腺癌（FTC）与髓样甲状腺癌（MTC）的患病率同样在2015年前呈上升态势，之后出现下降。研究发现PTC与其他类型TC在年龄分布、手术方式、再手术必要性及pTNM分期等方面存在显著差异：PTC患者的平均年龄显著低于其他类型TC患者（p<0.0001）。NIFTP的引入、PTMC主动监测的实施可能、个体化癌症医疗的发展以及COVID-19大流行这四项里程碑事件，可能共同影响了甲状腺癌的总体流行病学数据。
肿瘤(癌症)患者之家